GRPR recombinant proteins and antibodies

Gastrin-Releasing Peptide Receptor (GRPR) is a G protein-coupled receptor widely expressed in the central nervous system and various peripheral tissues, including the lung, stomach, and pancreas. GRPR binds to gastrin-releasing peptide (GRP) to activate downstream signaling pathways, regulating cell proliferation, differentiation, migration, and immune responses. Physiologically, GRPR is involved in the regulation of digestive system function, neurotransmitter release, and pain signaling, while also playing a significant role in the development and progression of various cancers.

In oncology, GRPR is considered a potential target for multiple tumor types, particularly prostate cancer, breast cancer, lung cancer, and gastric cancer. Overexpression of GRPR is associated with tumor cell proliferation, invasion, metastasis, and immune evasion. Research indicates that GRPR modulates immune cell activity within the tumor microenvironment, promoting tumor growth and resistance, making it a valuable target for cancer therapy and imaging diagnostics.

Drug development targeting GRPR primarily focuses on small molecule antagonists, monoclonal antibodies, and radiolabeled ligands. Small molecule antagonists inhibit GRPR signaling to block tumor cell proliferation and migration. Monoclonal antibodies specifically bind to GRPR, preventing GRP ligand interaction and modulating the tumor microenvironment. Radiolabeled ligands are being developed for tumor imaging and targeted radiotherapy, enabling precise cancer treatment strategies. As understanding of GRPR’s role in tumor progression and immune modulation deepens, more innovative GRPR-targeted therapies are expected to enter clinical trials in the coming years, providing new options for cancer treatment.

To assist in the development of GRPR targeted therapies, DIMA BIOTECH can now provide a full range of products and services for GRPR target. Products include active GRPR recombinant proteins, full-length GRPR proteins, GRPR reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of GRPR biotherapy, DIMA BIOTECH has also prepared a GRPR target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple GRPR IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.